文献速递新生儿儿童神经与发育行为

苯巴比妥与可乐定作为新生儿阿片戒断综合征二线药物的比较

Phenobarbital and Clonidine as Secondary Medications for Neonatal Opioid Withdrawal Syndrome.
PubMed 文献 · Pediatrics · 2021-01-01

校正混杂因素后,苯巴比妥组住院时间较可乐定组缩短10天,部分模型中吗啡疗程缩短7.5天,但苯巴比妥组出院时带药比例更高(78% vs 29%)。

要点

  • 接受吗啡和二级治疗的NOWS患儿中,苯巴比妥组住院时间较可乐定组缩短10天。
  • 部分模型中苯巴比妥组吗啡治疗时长较可乐定组缩短7.5天,峰值吗啡剂量无差异。
  • 苯巴比妥组出院时带二级药物比例显著高于可乐定组(78% vs 29%)。

核心结论

  • 在NOWS患儿中,当一线吗啡治疗未能控制症状时,加用苯巴比妥作为二级治疗较可乐定可缩短住院时间和吗啡治疗时长。
  • 但苯巴比妥组出院时更多仍在使用二级药物,需进一步研究评估其神经发育影响。

研究设计与样本

  • 回顾性队列研究,纳入来自30家医院的563例接受吗啡治疗的NOWS婴儿。
  • 采用方差分析和多变量线性回归控制相关混杂因素后比较组间结局。

主要发现

  • 校正协变量后,苯巴比妥组住院时间较可乐定组缩短10天,部分模型中吗啡治疗时长缩短7.5天。
  • 两组峰值吗啡剂量无差异。
  • 苯巴比妥组出院时带药比例高于可乐定组(78% vs 29%,P < .0001)。

关键数值与推荐

  • 主要结局指标为住院时间、阿片治疗时长和峰值吗啡剂量。
  • 苯巴比妥组出院带药比例78%,可乐定组29%,P < .0001。

临床怎么用

  • 对于吗啡一线治疗未能控制症状的NOWS患儿,可考虑加用苯巴比妥作为二级药物以缩短住院时间和吗啡疗程。
  • 需权衡苯巴比妥组出院时更常带药及潜在神经发育后果,并个体化决策。

局限性

  • 本研究为回顾性队列研究,可能存在未控制的混杂因素。
  • 原文未报告苯巴比妥对神经发育的长期影响,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Despite the neonatal opioid withdrawal syndrome (NOWS) epidemic in the United States, evidence is limited for pharmacologic management when first-line opioid medications fail to control symptoms. The objective with this study was to evaluate outcomes of infants receiving secondary therapy with phenobarbital compared with clonidine, in combination with morphine, for the treatment of NOWS. METHODS: We performed a retrospective cohort study of infants with NOWS from 30 hospitals. The primary outcome measures were the length of hospital stay, duration of opioid treatment, and peak morphine dose. Outcomes were compared by group by using analysis of variance and multivariable linear regression controlling for relevant confounders. RESULTS: Of 563 infants with NOWS treated with morphine, 32% (n = 180) also received a secondary medication. Seventy-two received phenobarbital and 108 received clonidine. After adjustment for covariates, length of hospital stay was 10 days shorter, and, in some models, duration of morphine treatment was 7.5 days shorter in infants receiving phenobarbital compared with those receiving clonidine, with no difference in peak morphine dose. Infants were more likely to be discharged from the hospital on phenobarbital than clonidine (78% vs 29%, P < .0001). CONCLUSIONS: Among infants with NOWS receiving morphine and secondary therapy, those treated with phenobarbital had shorter length of hospital stay and shorter morphine treatment duration than clonidine-treated infants but were discharged from the hospital more often on secondary medication. Further investigation is warranted to determine if the benefits of shorter hospital stay and shorter duration of morphine therapy justify the possible neurodevelopmental consequences of phenobarbital use in infants with NOWS.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Merhar SL, Ounpraseuth S, Devlin LA, et al. Phenobarbital and Clonidine as Secondary Medications for Neonatal Opioid Withdrawal Syndrome. Pediatrics. 2021. PMID: 33632932. doi:10.1542/peds.2020-017830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。